Literature DB >> 33314755

Second sialic acid-binding site of influenza A virus neuraminidase: binding receptors for efficient release.

Wenjuan Du1, Erik de Vries1, Frank J M van Kuppeveld1, Mikhail Matrosovich2, Cornelis A M de Haan1.   

Abstract

Influenza A viruses (IAVs) are a major cause of human respiratory tract infections and cause significant disease and mortality. Human IAVs originate from animal viruses that breached the host species barrier. IAV particles contain sialoglycan receptor-binding hemagglutinin (HA) and receptor-destroying neuraminidase (NA) in their envelope. When IAV crosses the species barrier, the functional balance between HA and NA needs to be adjusted to the sialoglycan repertoire of the novel host species. Relatively little is known about the role of NA in host adaptation in contrast to the extensively studied HA. NA prevents virion aggregation and facilitates release of (newly assembled) virions from cell surfaces and from decoy receptors abundantly present in mucus and cell glycocalyx. In addition to a highly conserved catalytic site, NA carries a second sialic acid-binding site (2SBS). The 2SBS preferentially binds α2,3-linked sialic acids and enhances activity of the neighboring catalytic site by bringing/keeping multivalent substrates in close contact with this site. In this way, the 2SBS contributes to the HA-NA balance of virus particles and affects virus replication. The 2SBS is highly conserved in all NA subtypes of avian IAVs, with some notable exceptions associated with changes in the receptor-binding specificity of HA and host tropism. Conservation of the 2SBS is invariably lost in human (pandemic) viruses and in several other viruses adapted to mammalian host species. Preservation or loss of the 2SBS is likely to be an important factor of the viral host range.
© 2020 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Entities:  

Keywords:  hemagglutinin; host range; influenza A virus; neuraminidase; second sialic acid-binding site; sialic acid

Year:  2020        PMID: 33314755     DOI: 10.1111/febs.15668

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  6 in total

1.  Analysis of the Evolution of Pandemic Influenza A(H1N1) Virus Neuraminidase Reveals Entanglement of Different Phenotypic Characteristics.

Authors:  Meiling Dai; Wenjuan Du; Carles Martínez-Romero; Tim Leenders; Tom Wennekes; Guus F Rimmelzwaan; Frank J M van Kuppeveld; Ron A M Fouchier; Adolfo Garcia-Sastre; Erik de Vries; Cornelis A M de Haan
Journal:  mBio       Date:  2021-05-11       Impact factor: 7.867

Review 2.  Development and Effects of Influenza Antiviral Drugs.

Authors:  Hang Yin; Ning Jiang; Wenhao Shi; Xiaojuan Chi; Sairu Liu; Ji-Long Chen; Song Wang
Journal:  Molecules       Date:  2021-02-04       Impact factor: 4.411

Review 3.  Influenza Neuraminidase Characteristics and Potential as a Vaccine Target.

Authors:  Sarah Creytens; Mirte N Pascha; Marlies Ballegeer; Xavier Saelens; Cornelis A M de Haan
Journal:  Front Immunol       Date:  2021-11-16       Impact factor: 7.561

4.  Intermolecular Mechanism and Dynamic Investigation of Avian Influenza H7N9 Virus' Susceptibility to E119V-Substituted Peramivir-Neuraminidase Complex.

Authors:  Sphamandla E Mtambo; Samuel C Ugbaja; Aganze G Mushebenge; Bahijjahtu H Abubakar; Mthobisi L Ntuli; Hezekiel M Kumalo
Journal:  Molecules       Date:  2022-03-02       Impact factor: 4.411

5.  Structural Investigations and Binding Mechanisms of Oseltamivir Drug Resistance Conferred by the E119V Mutation in Influenza H7N9 Virus.

Authors:  Samuel C Ugbaja; Sphamandla E Mtambo; Aganze G Mushebenge; Patrick Appiah-Kubi; Bahijjahtu H Abubakar; Mthobisi L Ntuli; Hezekiel M Kumalo
Journal:  Molecules       Date:  2022-07-08       Impact factor: 4.927

Review 6.  Respiratory mucus as a virus-host range determinant.

Authors:  Louisa E Wallace; Mengying Liu; Frank J M van Kuppeveld; Erik de Vries; Cornelis A M de Haan
Journal:  Trends Microbiol       Date:  2021-04-16       Impact factor: 17.079

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.